Dermoscopic findings of perifollicular pigmentation associated with vandetanib
Keywords:
cutaneous adverse events, tyrosine kinase inhibitor, pigmentation, dermoscopyPublished
2018-10-31
Issue
Section
Letter
License
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
1.
Dermoscopic findings of perifollicular pigmentation associated with vandetanib. Dermatol Pract Concept [Internet]. 2018 Oct. 31 [cited 2024 Apr. 17];8(4):340-1. Available from: https://dpcj.org/index.php/dpc/article/view/dermatol-pract-concept-articleid-dp0804a20